详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 自然指数

作者：

机构： [1]Toni Stephenson Lymphoma Center, Department of Hematology and HematopoieticCell Transplantation, Beckman Research Institute of City of Hope, Duarte, CA 91010,USA [2]Center for CAR T Cell Therapy, Department of Hematology and HematopoieticCell Transplantation, Beckman Research Institute of City of Hope, Duarte, CA 91010,USA [3]Department of Medical Oncology Cancer Center, West China Hospital, SichuanUniversity, Sichuan 910041, China [4]The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450001, China [5]The Second Affiliated Hospital of Dalian MedicalUniversity, Dalian 116044, China [6]Department of Pharmacology and PharmaceuticalSciences, School of Pharmacy, University of Southern California, CA 90007, USA [7]Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte,CA 91010, USA [8]Department of Pathology, City of Hope National Medical Center,Duarte, CA 91010, USA [9]Gehr Family Center for Leukemia Research, Department ofHematology and Hematopoietic Cell Transplantation, Beckman Research Instituteof City of Hope, Duarte, CA 91010, USA [10]Department of Pathology and LaboratoryMedicine, Weill Cornell Medical College, New York, NY 10065, USA

出处：

DOI：

ISSN：

摘要：

CAR T cells targeting CD19 provide promising options for treatment of B cell malignancies. However, tumor relapse from antigen loss can limit efficacy. We developed humanized, second-generation CAR T cells against another B cell-specific marker, B cell activating factor receptor (BAFF-R), which demonstrated cytotoxicity against human lymphoma and acute lymphoblastic leukemia (ALL) lines. Adoptively transferred BAFF-R-CAR T cells eradicated 10-day preestablished tumor xenografts after a single treatment and retained efficacy against xenografts deficient in CD19 expression, including CD19-negative variants within a background of CD19-positive lymphoma cells. Four relapsed, primary ALLs with CD19 antigen loss obtained after CD19-directed therapy retained BAFF-R expression and activated BAFF-R-CAR, but not CD19-CAR, T cells. BAFF-R-CAR, but not CD19-CAR, T cells also demonstrated antitumor effects against an additional CD19 antigen loss primary patient-derived xenograft (PDX) in vivo. BAFF-R is amenable to CAR T cell therapy, and its targeting may prevent emergence of CD19 antigen loss variants. Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 1 区

医学

小类 | 1 区细胞生物学 1 区医学：研究与实验

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区细胞生物学 1 区医学：研究与实验

第一作者：

第一作者机构： [1]Toni Stephenson Lymphoma Center, Department of Hematology and HematopoieticCell Transplantation, Beckman Research Institute of City of Hope, Duarte, CA 91010,USA

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

日	一	二	三	四	五	六

今天

清空